Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer

NCT03103152 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT03103152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03103152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2016
Completion date
March 31, 2020
Enrollment
104 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer